The Phase 1 dosing is a routine clinical milestone for a pre-revenue biotech. The key near-term catalyst is the September 30 educational event, which may provide context on NTCP modulation and the AX-0811 program. Traders should watch for any safety signals or biomarker data disclosed at the event, but the primary data readout is not until early January 2027.
Price Chart
Executive Summary
ProQR announced the first participant dosed in the Phase 1 study of AX-0811, a next-generation RNA editing oligonucleotide for cholestatic liver diseases including biliary atresia. The company also scheduled a virtual investor and analyst educational event for September 30, 2026, to review AX-0810 Phase 1 data and discuss the development strategy for NTCP modulation. This is an early clinical milestone with no financial data or efficacy results; the next catalyst is target engagement data expected in early January 2027.
Key Facts
- First participant dosed in Phase 1 study of AX-0811 in healthy volunteers.
- AX-0811 is an AI-discovered RNA editing oligonucleotide targeting NTCP for cholestatic liver diseases.
- Preclinical data showed greater potency and longer half-life vs AX-0810.
- Phase 1 target engagement data for first two cohorts expected in early January 2027.
- Virtual investor/analyst event scheduled for September 30, 2026.
- No financial results, guidance, or material agreements disclosed.
Financial Impact
No financial data provided; early clinical-stage company with no revenue from product sales.
Risk Factors
- Preclinical potency/half-life advantages may not translate to humans.
- Phase 1 data in healthy volunteers may not predict safety/efficacy in patients.
- No revenue or near-term commercialization; fully dependent on pipeline success.
- Dilution risk from existing shelf registration statements (F-3 filings referenced).
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001104659-26-106138 |
| Document: tm2624953d1_6k.htm | 0001104659-26-106138 |
| Document: 0001104659-26-106138-index-headers.html | 0001104659-26-106138 |
| Document: 0001104659-26-106138-index.html | 0001104659-26-106138 |
| Document: 0001104659-26-106138.txt | 0001104659-26-106138 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 23, 2026 4w ago | 6-K | $1.70 $1.66 | ▼ −2.35% | ▼ −1.68% | $1.24 (−27.06%) |
Sep 9, 2026 6w ago | 6-K | $1.99 $1.86 | ▼ −6.53% | ▼ −5.44% | $1.24 (−37.69%) |
Jul 16, 2026 14w ago | EFFECT | $1.67 $1.79 | ▼ −7.19% | ▼ −8.86% | $1.24 (+25.75%) |
Jun 25, 2026 17w ago | 6-K | $1.53 $1.81 | ▼ −18.30% | ▼ −16.13% | $1.24 (+18.95%) |
Jun 25, 2026 17w ago | 424B5 | $1.53 $1.81 | ▲ +18.30% | ▲ +16.13% | $1.24 (−18.95%) |
Jun 2, 2026 20w ago | 6-K | $1.47 $1.41 | ▼ −4.08% | ▼ −0.26% | $1.24 (−15.65%) |
May 12, 2026 23w ago | 6-K | $1.60 $1.51 | ▲ +5.63% | ▲ +5.70% | $1.24 (+22.50%) |
Apr 30, 2026 25w ago | 6-K | $1.57 $1.72 | ▲ +9.55% | ▲ +7.83% | $1.24 (−21.02%) |
Apr 30, 2026 25w ago | Press Release | $1.57 $1.72 | ▲ +9.55% | ▲ +7.83% | $1.24 (−21.02%) |
Apr 8, 2026 28w ago | 6-K | $1.98 $1.95 | ▼ −1.52% | ▼ −4.70% | $1.24 (−37.37%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers